About InVivoMAb anti-human CD32 (FcγRIIA)
The IV.3 monoclonal antibody reacts with human CD32 also known as FcγRII and FCRII, a 40 kDa polymorphic transmembrane glycoprotein and an Ig superfamily member. CD32 is expressed on monocytes/macrophages, granulocytes, platelets and B cells. CD32 enables interaction between Fc γ RII-expressing cells and opsonized antigen or IgG-containing immune complexes. This allows CD32 to function in the activation or inhibition of immune responses including degranulation, phagocytosis, ADCC, cytokine release, and B cell proliferation. The IV.3 antibody has been shown to block the biological effects of CD32 in vitro. Additionally, IV.3 f(ab")2 fragments have been used to block CD32 in vivo in transgenic mice expressing human CD32.
InVivoMAb anti-human CD32 (FcγRIIA) Specifications
| Isotype | Mouse IgG2b |
| Recommended Isotype Control(s) | InVivoMAb mouse IgG2b isotype control, unknown specificity(BE0086) |
| Recommended InVivoPure Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer(IP0070) |
| Immunogen | Human K562 leukemia cell line |
| Reported Applications |
|
| Endotoxin |
|
| Purity |
|
| Formulation |
|
| Sterility | 0.2 μM filtered |
| Production | Purified from tissue culture supernatant in an animal free facility |
| Purification | Protein G |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| RRID | AB_2687707 |
| Molecular Weight | 150 kDa |
